News

Jan 31,2023

C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF V600 Mutant Solid Tumors

Jan 27,2023

Twist Bioscience Begins Shipping Commercial Product from Synthetic DNA Manufacturing Factory of the Future

Jan 10,2023

Twist and Astellas Partner on Antibody Discovery Program

Jan 05,2023

Immune-Onc Therapeutics Announces Close of Series B Extension Financing, Bringing Total Round to $131 Million

Dec 31,2022

ONCOC4 ANNOUNCES FIRST PATIENT DOSED IN PRESERVE-004, A PHASE 2 CLINICAL TRIAL OF ONC-392 IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) IN PATIENTS WITH PLATINUM-RESISTANT OVARIAN CANCER

Dec 15,2022

Avirmax CMC Inc. Successfully Manufactured and Delivered to a Client the First Lot of rAAV Drug Product for a Monkey Toxicology Study

Nov 30,2022

KBP Presents Results of the Hepatic Impairment Study and Drug-Drug Interaction Study of Ocedurenone (KBP-5074) at ASN Kidney Week 2022

Nov 29,2022

Aravive Announces Fast Track Designation of Batiraxcept for Treatment of ccRCC

End of content

No more pages to load

Next page